Have you or your loved ones been diagnosed with acute lymphoblastic leukemia (all)?

You may be eligible to participate in a acute lymphoblastic leukemia (all) clinical trial.

Have you or your loved ones been diagnosed with acute lymphoblastic leukemia (all)? You may be eligible to participate in a acute lymphoblastic leukemia (all) clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Acute Lymphoblastic Leukemia (ALL) Clinical Trial
NCT02303821 | Phase 1 | Interventional
Amgen
Sponsored by
Amgen

Have you or your loved ones been diagnosed with acute lymphoblastic leukemia (all)?

You may be eligible to participate in a acute lymphoblastic leukemia (all) clinical trial.

Have you or your loved ones been diagnosed with acute lymphoblastic leukemia (all)? You may be eligible to participate in a acute lymphoblastic leukemia (all) clinical trial.

Recruiting

Male & Female

1 Month -
21 Years

This study is looking to recruit 118 Participants

The purpose of Phase 1b of this study is to: - Asses the safety, tolerability and activity of carfilzomib, alone and in combination with induction chemotherapy, in children with relapsed or refractory acute lymphoblastic leukemia (ALL). - Determine the maximum tolerated dose (MTD) and to recommend a phase 2 dose of carfilzomib in combination with induction chemotherapy. The purpose of Phase 2 of this study is to compare the rate of complete response (CR) of carfilzomib in combination with vincristine, dexamethasone, PEG asparaginase, daunorubicin (VXLD) at the end of induction therapy to an appropriate external control.